Method Enables Food Producers to Rapidly Identify and Mitigate Recurring Listeria in Facilities
ITHACA, N.Y. — Rheonix Inc., a manufacturer of microfluidic workstations and assays for molecular testing, will exhibit and share data at the International Association for Food Protection (IAFP) 2023 Annual Meeting in Toronto, Ontario, Canada, July 16-19. The IAFP Annual Meeting is the preeminent food safety conference focused on current and emerging food safety issues. Rheonix will showcase a… Read More »
Molecular sample-to-answer method enables low-level detection of Cyclospora in food and environmental samples
ITHACA, N.Y. — Rheonix Inc., a manufacturer of microfluidic workstations and assays for molecular testing, announced that it has completed development of a fully automated test for the detection of Cyclospora cayetanensis in food and environmental samples. The development was conducted in collaboration with scientists at the Office of Applied Research and Safety Assessment (OARSA) within the Center for… Read More »
Eurofins Microbiology Laboratory, Inc. in Mounds View, MN is proud to announce both its new partnership with Rheonix and new offering of the Rheonix Listeria PatternAlert™ assay for Listeria presumptive samples.
The Listeria PatternAlert™ assay enables rapid identification of recurring patterns of Listeria contamination across locations and time. The assay provides a client-specific database of Listeria patterns over time. Customers can use the assay as an alternate to cultural confirmation or… Read More »
ITHACA, N.Y. — Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay to include home collection using the Rheonix Laboratories COVID-19 PCR Test Saliva Home Collection Kit. Rheonix’s fully automated sample-to-answer COVID-19 assay received its initial EUA for use on a range of respiratory specimens on April 29, 2020. The EUA has… Read More »
Rheonix Laboratories LLC is a New York State-permitted CLIA laboratory that provides easy, streamlined testing for organizations and community members
ITHACA, N.Y. — Rheonix Inc., a manufacturer of a highly advanced microfluidic molecular testing platform, announced the opening of Rheonix Laboratories LLC, a CLIA-certified clinical laboratory located in Ithaca, New York. Rheonix Laboratories is permitted by New York State to provide COVID-19 PCR testing and results, and will be partnering with… Read More »
New addition to Rheonix leadership adds expertise in infectious diseases and global epidemic response
ITHACA, N.Y. — Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, announced the appointment of Stephen J. Thomas, M.D., as Chief Medical Officer and member of the Rheonix Board of Directors.
"I am delighted to welcome Dr. Thomas to the Rheonix Board and as our Chief Medical Officer," said Greg Galvin, President, CEO and Chairman of… Read More »
Low-cost, scalable, sample-to-answer system provides flexibility and true walk-away testing
ITHACA, N.Y. — Rheonix Inc., an innovative leader in highly multiplexed pathogen detection, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance of its automated Encompass MDx® Workstation, along with its STI TriPlex™ Assay and Male Urine Collection Kit for the detection of sexually transmitted infections (STI).
“Rheonix is pleased to announce our FDA 510(k) approval for a… Read More »
Fully automated, scalable Rheonix method shows robust detection of variants
ITHACA, N.Y. — Rheonix Inc. today announced that the Rheonix COVID-19™ MDx Assay will detect the newly emerging omicron variant of SARS-CoV-2, as well as other variants of public health concern. The company’s assessments indicate that its COVID-19 MDx Assay detects all SARS-CoV-2 variants of concern and variants being monitored by the World Health Organization (WHO) and U.S. Centers for Disease… Read More »
ITHACA, N.Y. — Rheonix Inc. today announced the appointment of Roy Proujansky, M.D., and Irving Nachamkin, DrPH, MPH, to its board of directors.
"I'm honored to welcome Drs. Proujansky and Nachamkin to our board," said Greg Galvin, Ph.D., founder and CEO of Rheonix. "They join Rheonix at an exciting time as we provide critical testing solutions to address the pandemic and broaden our clinical diagnostic portfolio. The addition of these directors complements… Read More »
ITHACA, N.Y. — Rheonix Inc. announced today that the United States Food and Drug Administration (FDA) has issued an expanded Emergency Use Authorization (EUA) for the Rheonix COVID-19™ MDx Assay and now allows the use of saliva as an approved sample type. The fully automated sample-to-answer assay was initially authorized for use on a range of respiratory specimens under EUA on April 29, 2020.
The ability to test saliva samples for the… Read More »